Between 2003 and 2015, Elizabeth Holmes raised over $700 million for Theranos on the claim that her proprietary blood testing device could run hundreds of tests from a single finger-prick. The technology never worked reliably. The company secretly used modified commercial analyzers for most tests while telling investors, partners, and regulators otherwise. Patients received false HIV, cancer, and pregnancy results. Holmes was convicted on four counts of wire fraud in January 2022 and sentenced to 11 years in federal prison.
In 2003, Elizabeth Holmes dropped out of Stanford University at age 19 with a vision: to revolutionize medical diagnostics through a proprietary device that could run hundreds of blood tests from a single finger-prick sample. Traditional blood testing required venipuncture — drawing blood from a vein with a needle and syringe — and multiple vials to run comprehensive panels. Holmes claimed her technology would require only 1/100th to 1/1000th the blood volume, make testing painless and convenient, and deliver results faster and cheaper than existing laboratory methods.
The company she founded, Theranos — a portmanteau of "therapy" and "diagnosis" — raised its first venture capital in 2004. Over the next decade, Holmes built one of Silicon Valley's most celebrated startups, raising over $700 million from prominent investors and assembling a board of directors that read like a roster of American power: former Secretaries of State George Shultz and Henry Kissinger, former Defense Secretary James Mattis, former Wells Fargo CEO Richard Kovacevich, and media mogul Rupert Murdoch.
By 2013, Theranos had formed partnerships with Walgreens and Safeway to offer blood testing services in retail locations. The company operated CLIA-certified clinical laboratories in Newark, California and Scottsdale, Arizona, processing real patient samples that physicians used to make medical decisions. Holmes appeared on magazine covers, delivered a TED talk, and was featured in documentaries. The narrative was irresistible: a young female entrepreneur disrupting a stagnant industry, making healthcare more accessible, potentially saving lives.
The only problem was that the core technology — the proprietary blood analyzer called the Edison — did not work reliably. And Elizabeth Holmes knew it.
Theranos claimed its Edison device could perform up to 240 different tests from a single finger-prick of blood collected in a proprietary "nanotainer" — a small tube holding approximately 10-20 microliters. The device would analyze this tiny sample using miniaturized laboratory techniques, providing results within hours at a fraction of the cost of traditional laboratories.
Internal validation studies told a different story. As early as 2008, Theranos engineers documented extensive quality control failures. Proficiency testing — in which laboratories receive samples with known values to verify accuracy — showed pass rates as low as 65% for some tests on the Edison, well below the 80% minimum required by federal regulators. Results were erratic. The same sample tested multiple times often produced wildly different values.
"We could never get it to work consistently. The chemistry was flawed. But nobody wanted to hear that."
Erika Cheung, Former Theranos Lab Associate — Testimony at Holmes trial, 2021Rather than acknowledge these failures, Theranos implemented a secret workaround. Beginning in 2013, when the company launched patient testing services at Walgreens, it processed the vast majority of tests using modified commercial analyzers purchased from Siemens. These were conventional machines used in clinical laboratories worldwide. Theranos engineers modified them to run on smaller sample volumes by diluting the blood samples — a process that can introduce additional inaccuracy, particularly when blood volumes are already extremely small.
Of approximately 890,000 patient tests Theranos performed in 2014, fewer than 100,000 used the proprietary Edison device. Yet the company continued to tell investors, partners, and the public that its revolutionary technology was successfully running patient tests. This was not a simplification or exaggeration. It was a categorical misrepresentation of material fact.
The fraud was not merely financial. Between 2013 and 2016, Theranos processed blood tests for real patients seeking medical care. Physicians ordered these tests to diagnose conditions, monitor chronic diseases, and make treatment decisions. The tests were billed to Medicare, Medicaid, and private insurance. When results were inaccurate, patients and doctors made decisions based on false information.
Documented cases included patients receiving false positive results for HIV, false results for cancer markers, incorrect pregnancy test results, and erroneous readings for conditions like hyperthyroidism that led to unnecessary medical interventions. One patient, Brittany Gould, testified that she received a positive test for HIV from Theranos. She was six months pregnant. The result was false — but she spent weeks believing she had HIV and might have transmitted it to her unborn child.
In January 2016, the Centers for Medicare & Medicaid Services (CMS) conducted a surprise inspection of Theranos's Newark laboratory following complaints. The inspection found conditions that posed "immediate jeopardy to patient health and safety" — the most serious category of deficiency. CMS inspectors documented 66 deficiencies including failure to maintain quality control, use of unvalidated test methods, and inadequate proficiency testing.
The FDA followed with a warning letter stating that Theranos's nanotainer blood collection device was an unapproved medical device being marketed without clearance or approval, and that it could produce erroneous results. The agency ordered Theranos to stop using the device for all tests except the single herpes test that had received explicit FDA approval.
Theranos was not merely optimistic or premature in its claims. Evidence presented at trial documented a systematic pattern of deception maintained through multiple mechanisms:
Fabricated Validation Reports: In 2008, Theranos provided Pfizer with validation reports that bore Pfizer's corporate logo and formatting, creating the impression that Pfizer scientists had independently validated the technology. In reality, the reports were prepared by Theranos staff. The data in the reports did not accurately reflect actual test performance. When Pfizer scientists conducted their own evaluation, they found the technology unreliable and declined to pursue a partnership. Holmes and Balwani subsequently used the Pfizer-logoed reports to convince other investors and partners that a major pharmaceutical company had endorsed the technology — without disclosing that the reports were created by Theranos, not Pfizer.
Investor Misrepresentations: Holmes provided investors with financial projections claiming Theranos would generate $100 million in revenue in 2014 and $1 billion by 2015. Actual 2014 revenue was approximately $100,000. Holmes told investors that Theranos devices were being used on military medevac helicopters in the field; in reality, a few demo units had been provided for evaluation but were never deployed operationally. Holmes claimed pharmaceutical companies were paying Theranos tens of millions for validation studies; actual payments were a small fraction of claimed amounts, and some claimed partnerships did not exist.
"Elizabeth Holmes lied to investors. She lied to patients. She lied to the media. And she lied to her own employees."
Assistant US Attorney Robert Leach — Opening Statement, United States v. Holmes, September 2021Secrecy and Compartmentalization: Theranos operated under extreme secrecy unusual even for Silicon Valley. Employees signed extensive non-disclosure agreements. The laboratory was divided into separate areas with badge access restrictions preventing most employees from seeing what occurred in other sections. Employees who raised concerns about data manipulation or quality control failures were terminated or threatened with litigation. When partners like Walgreens and Safeway requested detailed technical validation data, Theranos refused, citing trade secret protections.
Legal Intimidation of Whistleblowers: When former employees spoke to reporters or regulators, Theranos responded with the law firm Boies Schiller Flexner, which sent threatening letters demanding retractions and threatening multi-million dollar lawsuits. Tyler Shultz — a former research engineer and grandson of board member George Shultz — received letters threatening him with litigation after he raised quality control concerns with New York state regulators and spoke with a Wall Street Journal reporter. His family spent approximately $400,000 in legal fees defending him. The intimidation campaign was designed to create a chilling effect on other potential whistleblowers.
In April 2015, Wall Street Journal reporter John Carreyrou received a tip from a pathologist concerned about Theranos test accuracy. Over the following months, Carreyrou interviewed dozens of former employees, reviewed internal documents, and confirmed that Theranos was secretly using commercial analyzers for most tests while publicly claiming to use proprietary technology.
Theranos responded aggressively. The company hired Boies Schiller Flexner to threaten Carreyrou and the Journal with litigation. David Boies — founder of the firm and a Theranos board member — personally met with Journal editors to argue that the reporting was false and should not be published. Boies attempted to pressure Rupert Murdoch, who owned the Journal's parent company and had personally invested $125 million in Theranos, to kill the story. Journal editors stood by the reporting.
Carreyrou's first article published on October 15, 2015: "Hot Startup Theranos Has Struggled With Its Blood-Test Technology." The article revealed that Theranos used its proprietary device for only a small fraction of tests and that former employees had serious concerns about accuracy. Additional investigative pieces followed through 2016, each adding documentary detail.
The Journal investigation triggered federal action. CMS inspected the Newark laboratory in August 2015 and issued its deficiency findings in January 2016, threatening to revoke Theranos's laboratory license and ban Holmes and Balwani from operating laboratories. The FDA asserted jurisdiction over the nanotainer device and issued a warning letter. Walgreens suspended and then terminated its partnership. By mid-2016, Theranos had closed its clinical laboratories and ceased patient testing.
In March 2018, the SEC charged Holmes and Balwani with "massive fraud" involving material misrepresentations to investors. Holmes settled without admitting wrongdoing, paying a $500,000 penalty and agreeing to be barred from serving as a public company officer or director for 10 years — penalties the SEC acknowledged were limited by Holmes's lack of remaining assets.
On June 15, 2018, a federal grand jury indicted Holmes and Balwani on nine counts of wire fraud and two counts of conspiracy. The indictment alleged two fraud schemes: one targeting investors and one targeting patients and doctors. Prosecutors would need to prove Holmes and Balwani made false statements with intent to defraud, and that victims suffered harm as a result.
Holmes's trial began in September 2021 after multiple delays. The prosecution presented testimony from 29 witnesses over three months, including former employees who documented quality control failures, investors who described Holmes's misrepresentations, and patients who received false results. Prosecutors introduced internal emails and text messages showing Holmes was directly aware of the Edison's problems as early as 2008.
Holmes testified in her own defense, claiming she believed the technology would eventually work and that failures were temporary engineering challenges. Her attorneys argued she was not criminally responsible for optimistic projections common in startup culture. Holmes also made allegations that Balwani — her former boyfriend and business partner — had psychologically abused and controlled her, though the judge ruled this "mental disease" defense could not be used to negate intent for the fraud charges.
"Ms. Holmes chose fraud over business failure. She chose to be dishonest with investors and patients. That choice was criminal."
Judge Edward Davila — Sentencing Hearing, United States v. Holmes, November 2022On January 3, 2022, the jury convicted Holmes on four of eleven counts: one count of conspiracy to defraud investors and three counts of wire fraud against specific investors. She was acquitted on counts related to defrauding patients and on charges involving other investors where prosecutors could not prove Holmes made direct false statements. The mixed verdict reflected the jury's conclusion that Holmes had defrauded investors but that evidence was insufficient on the patient-related charges.
Balwani's trial followed in spring 2022. Because he did not have Holmes's public profile or testimony claiming abuse, prosecutors could focus more directly on his operational role running the laboratories that produced inaccurate patient results. In July 2022, Balwani was convicted on all 12 counts — four related to investor fraud and eight related to patient fraud.
In November 2022, Judge Edward Davila sentenced Holmes to 135 months (11 years, 3 months) in federal prison. In December 2022, he sentenced Balwani to 156 months (13 years). Both were ordered to pay $452 million in restitution jointly to defrauded investors. Holmes is currently incarcerated at Federal Prison Camp Bryan in Texas; her release date is projected for 2032. Balwani is serving his sentence at a federal facility in California.
The Theranos case is significant not merely for its scale but for what it reveals about systemic failures in venture capital, corporate governance, media narratives, and regulatory oversight.
Venture Capital Due Diligence Failures: Sophisticated investors including venture capital firms with extensive technical expertise invested hundreds of millions without independently verifying core technology claims. Theranos exploited trade secret protections to refuse detailed technical disclosure, and investors accepted this. The case demonstrates how narrative and founder charisma can override technical verification, particularly when investors fear missing the next major innovation.
Board Composition and Oversight: Theranos assembled a board heavy with political and military figures but light on scientists and medical professionals who could evaluate the core technology claims. Board members like George Shultz and James Mattis lent credibility but lacked expertise to provide meaningful oversight. The board structure prioritized external legitimacy over internal accountability.
Regulatory Gaps in Laboratory Testing: Laboratory-developed tests have historically operated under minimal FDA oversight. This regulatory gap allowed Theranos to process hundreds of thousands of patient tests using devices that would not have survived conventional medical device approval processes. Subsequent policy discussions have focused on closing these gaps.
The Rarity of Criminal Prosecution: Corporate fraud typically results in civil settlements and monetary penalties without individual criminal accountability, particularly for executives at well-funded companies. The Theranos prosecutions were notable for resulting in substantial prison sentences for both the CEO and the COO. This distinguishes it from cases like Enron (where CEO Jeffrey Skilling served 12 years) but contrasts sharply with the 2008 financial crisis, where no major bank executives were criminally prosecuted despite widespread fraud.
The case also illustrates the essential role of whistleblowers and investigative journalism in exposing fraud that sophisticated investors, regulators, and corporate boards failed to detect. Tyler Shultz, Erika Cheung, and other former employees risked legal retaliation to document what was happening inside the company. John Carreyrou persisted despite legal threats and pressure from powerful interests. Without them, Theranos might have continued operating for years, harming additional patients.
Theranos was not a case of startup optimism or premature commercialization. The documentary record — internal emails, validation reports, regulatory inspection findings, and testimony under oath — establishes that Elizabeth Holmes and Ramesh Balwani knowingly made false statements about technology that did not work, used those false statements to raise hundreds of millions from investors, and deployed unreliable testing devices to process real patient samples that affected medical decision-making.
Holmes claimed in testimony that she believed the technology would eventually work and that she was simply projecting future success. But prosecutors demonstrated through her own emails and testimony from engineers that she knew, as early as 2006, that the Edison was not reliably producing accurate results. She knew pharmaceutical companies had rejected the technology after independent evaluation. She knew Theranos was using commercial analyzers for most patient tests while telling partners and investors the opposite. She approved falsified validation reports. She directed employees to conceal information from regulators.
This was not negligence. It was deliberate, calculated fraud maintained over years through secrecy, intimidation, and exploitation of gaps in regulatory oversight and investor due diligence.
The convictions and sentences represent partial accountability. They do not restore the $700 million lost by investors. They do not undo the harm to patients who received false diagnoses. But they establish a documentary record of corporate fraud and individual criminal responsibility that will serve as a reference point for future cases — and as evidence that even in Silicon Valley, fraud has consequences.